Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors Manu JaggiSudhanand PrasadAnand C. Burman PRECLINICAL STUDIES 24 January 2008 Pages: 489 - 504
Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas Anu T. SinghManu JaggiAnand C. Burman PRECLINICAL STUDIES 06 March 2008 Pages: 505 - 516
CPT21, a novel compound with anti-proliferative effect against gastric cancer cell SGC7901 Bo ZhangYu LuoBo Yang PRECLINICAL STUDIES 19 February 2008 Pages: 517 - 524
Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assay Xiao-lei LiJun-yan LiuZhi Yao PRECLINICAL STUDIES 09 February 2008 Pages: 525 - 529
Aberrant crypt foci and AgNORs as putative biomarkers to evaluate the chemopreventive efficacy of pronyl-lysine in rat colon carcinogenesis Jayabal Panneer SelvamSelvaraj AranganathanNamasivayam Nalini PRECLINICAL STUDIES 29 February 2008 Pages: 531 - 540
Optimal modeling for phase I design of a two drug combination—results of a phase I study of cisplatin with 9-nitrocamptothecin S.-J. LeeM. GounderC. F. Verschraegen PHASE I STUDIES 04 July 2008 Pages: 541 - 551
Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease I. TamaskarT. MekhailR. M. Bukowski PHASE I STUDIES 15 July 2008 Pages: 553 - 559
O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma Nicolas PenelCorinne DelcambreFrédéric Mouriaux PHASE II STUDIES 13 June 2008 Pages: 561 - 565
Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer E. TopuzD. DerinA. Aydıner PHASE II STUDIES 02 September 2008 Pages: 567 - 572